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Introduction. Navarra has the highest incidence of diﬀerentiated thyroid cancer in Spain. The aim of this study was to review its
management carried out by the Navarra’s multidisciplinary Thyroid Disease Unit, from 1987 to 2003. Material and Methods.
325 patients were studied to ﬁnd the incidence, prevalence, and prognostic factors. Statistical analysis comprised univariate
and multivariate Cox proportional hazards regression models for survival and tumor recurrence. Results. The average annual
incidencewas3.6per100,000inhabitants,withaﬁnalprevalenceof82.4per100,000.Regardingsurvivalandrecurrence,statistical
signiﬁcancewasobservedforstageIV,follicularcarcinoma,capsularandprethyroidmusclesinvasion,andT4group.Onlysurvival
was related to tumour size larger than 40mm. Only recurrence was related to lymph node metastases and radioiodine dose higher
than100mCi.Conclusions.Attendanceofpatientsinafunctionalunitsettinghasallowedustoclassifythemintothreeriskgroups.
1.Introduction
Diﬀerentiated thyroid cancer (DTC) is becoming more
frequent. The highest incidence in Spain is found in the
region of Navarra [1–3]. Recent research in tyrosine kinase
pathogenic activity and inhibitors is becoming more rele-
vant; nowadays, however, related treatments are used only
in selected patients [4]. Therefore, currently surgery is the
only treatment option that can cure it. If necessary, it can
be complemented by radioiodine and suppressive hormone
therapy. When very low risk papillary microcarcinoma is
detected, it may be suﬃcient to perform a less extensive
surgery [5–8]. On the other hand, when high-risk DTC is
found, it is mandatory to complete thyroid intervention with
a level VI of Robinson [9]l y m p h a d e n e c t o m yb e c a u s ew i t h
this approach local recurrence is lower [9–11].
Recent changes in guidelines have modiﬁed DTC treat-
ment and long-term follow-up. Recombinant human thy-
rotropin is widely used to avoid levothyroxine treatment
withdrawal in thyroglobulin (Tg) detection. High levels of
stimulated Tg are considered reliable data and the most sen-
sitive one for early diagnosis of persistent/recurrent disease.
A high-resolution ultrasound (US) [12] image obtained by
an expert provider can supply important information for
diagnosis, staging, and follow-up, and it guides ﬁne needle
aspiration cytology (FNAC) [13].
In this study, we set the following objectives.
(i) To analyse the incidence and prevalence of DTC
in the representative population of the region of
Navarra.
(ii) Todescribedemographiccharacteristics,tumorchar-
acteristics, chosen treatment, and results during2 ISRN Oncology
follow-up (cure, persistent/recurrent disease, and
death [14]).
(iii) To evaluate the eﬀect of above-mentioned data on re-
currence or mortality, by using statistical analysis.
(iv) To determine prognostic factors; identifying risk
groups and, if possible, suggesting criteria focused on
the improvement of treatment, management, sur-
vival, and low recurrence rate.
Our data have come from the setting of a functional unit,
known in our hospital as the “Thyroid Disease Unit.” It
is composed of a multidisciplinary team of specialists
(surgeons, endocrinologists, pathologists, and radiologists)
interested in this ﬁeld. This Unit treats nearly every patient
(more than 90%) suﬀering from DTC in the public health
system of Navarra.
We obtained signiﬁcant predictive variables in the uni-
variate and multivariate statistical analysis, which are associ-
ated with survival and persistent/recurrent disease.
2. Methods
Our research is deﬁned as an observational, historic cohorts,
descriptive, and analytical study. It includes patients who
have been diagnosed with DTC, treated and followed from
1987 until 2003 (17 years) by the Thyroid Disease Unit.
From the creation of this unit, data for variables and clinical
outcomes have been collected in a database. Following
international guidelines, patients were assessed in the out-
patient clinic and then the database was updated. The
information used was included in the oﬃcial hospital cancer
registryandﬁles,sotheprocesswasbackedupbylocalhealth
law and approved by the ethics commitee. Eight patients
missed in the follow-up were contacted. They lived in a
diﬀerent region but they were able to provide the required
information, therefore they were included in the ﬁnal results.
In the ﬁrst ﬁve years, our population mean was 518241
people, from 1992 to 1996 it was 520622 people, from 1997
to 2001 it was 567337 people, and the last two years it was
560243people.Intheregionalhospitalofourareaofinterest,
there was not a public cancer registry available. Nevertheless,
we assume that there are few cases detected in it.
Studied variables were as follows.
(i) Gender and age at the time of surgery. We analysed
two groups separately; younger than 45 years old and
equal/older than 45 years old at that moment, as
indicated in TNM [15–17] staging system.
(ii) Result of presurgical FNAC. We discriminated four
groups; suspicious, malignant, not valid, and benign
cytology.
(iii) Tumor classiﬁcation; DTC was classiﬁed in papil-
lary carcinoma (PC) or follicular carcinoma (FC)
comprising H¨ urthle carcinoma, as recommended by
current pathological classiﬁcation. Then, we counted
PC or FC and their pathological variants if available.
(iv) Tumor size, expressed in milimeters. In seven
patients, it was not reported, so those were labelled
as Tx.
(v) Surgicaltreatmentonthethyroid;thekindofsurgical
procedure of the primary tumor.
(vi) Surgical treatment of cervical lymph node metas-
tases; number of lymphadenectomies performed.
(vii) Surgical complications with in-patients, once they
arrivedatthesurgicalward,werecompiled.Themost
important and frequent ones were recurrent nerve
palsy and deﬁnitive hypocalcemia after parathy-
roid injury. Asphyctic hematoma was not included
because it usually happens few hours after surgery,
and it is managed by anaesthetics.
(viii) TNMstagingsystematthetimeofdiagnosis.Weused
the 6th edition pTNM system.
(ix) Thyroid capsule invasion; whether the primary
tumor inﬁltrates into the glandular capsule, meaning
an advanced stage, or not.
(x) Cervical muscle involvement by the primary tumor.
(xi) Unifocalormultifocal tumorin thegland; numberof
malignant locations in the thyroid.
(xii) Radioiodinetreatment;numberoftreatmentsessions
and total cumulative dose of I-131 in each patient.
(xiii) Positiveantithyroglobulinautoantibodies;numberof
patients aﬀected.
The descriptive study of all these items was executed in a
ﬁrst instance. Later, statistical models were built for analysis
of data: univariate model for survival, univariate model for
persistent/recurrent disease, multivariate model for survival,
and multivariate model for persistent/recurrent disease,
always using Proportional Risks Cox Regression. We also
show survival curves and the 5- and 10-year survival rates
of signiﬁcant variables. The outcomes of recurrence and
persistent disease are grouped together due to their low
incidence (below 4%). Also, by doing such statistical analysis
itiseasiertodevelopandtounderstand.Thesoftwarechosen
w a sS P S S1 7 . 0f o rW i n d o w s .
3. Results
325 patients underwent surgical treatment for their DTC
(100%). Annual incidence resulted in 3.6 per 100000 inhabi-
tants, and prevalence was 82.4 per 100000 inhabitants at the
time of December 2003.
The ratio for women reached 80%. Our population
can be considered young, given that 52.61% were under
45 years old. The presurgical FNAC result was suspicious
or malignant in 75%. Regarding tumor classiﬁcation, PC
was diagnosed in 63.38%, with a mean age of 42.90 years
o l d( r a n g e1 2t o7 9y e a r so l d )a n dm e a nt u m o rs i z eo f
21.75mm (range 1 to 80mm). In FC, mean age was 49.56
years old (range 15 to 83 years old) and mean tumor size
was 40.89mm (range 10 to 100mm). Tumor size was below
40mm in 79% and below 20mm in 42%.
Total thyroidectomy with any kind of lymphadenectomy
was the surgical procedure in 95.69%, detecting positive
lymph nodes in 21.23% of them. Surgical complicationsISRN Oncology 3
collected were as follows: 4% deﬁnitive recurrent nerve
palsy,1.8%deﬁnitivehypoparathyroidism,and0.3%surgical
wound infection.
Most patients belonged to early tumoral stages; 78.46%
were included in stages I and II of TNM system. Details of T
and N distribution and stages are shown in Table 1.
Thyroid capsules were aﬀected in nearly 13%, and in
37 subjects, cervical muscle involvement was reported.
Multifocal tumors were found in 32.61%.
Radioiodine treatment was used for 97.53% individuals.
About autoimmunity, we detected positive antithyrog-
lobulin antibodies in 22 patients, with the following charac-
teristics: 90% PC, mean tumor size of 25.9mm, mean age
of 39.5 years old, positive cervical lymph nodes in 59%, and
recurrent disease in 9%.
During follow-up, patients were considered to be free of
disease when symptoms were absent, physical examination
was negative as were image exams, and Tg was undetectable
togetherwiththyrotropinhigherthan30mUI/Landnegative
antibodies. 77.55% of patients fulﬁlled these criteria. On the
other hand, 4% of patients have died (8 with PC and 5 with
FP) and 3.69% presented with recurrent disease.
Finally, the ﬁnal 14.76% corresponded to subjects that
had some biochemical abnormality during follow-up, usu-
ally a single elevation of thyroglobulin, but could not
be included in the cured group nor in those who had
tumor evidence on radiology exams. Distant metastases were
detected in 9 (2.8%) patients. The most frequent target
was lung; 8 patients (89% of metastatic disease). In four of
them, lung metastases coexisted with bone (3 patients) or
brain (1 patient) location. One patient diagnosed of multiple
metastatic sites suﬀered from subcutaneous spread. Every
distant spread was diagnosed after ﬁrst surgical treatment.
The summary of descriptive data is shown in Table 1.
In the univariate model for survival, we found statistical
signiﬁcance in the variables; capsule invasion, prethyroid
muscleinvolvement,tumorsizelargerthan40mm,T4group
of TNM (with regard to the T1 group and to the “rest of T”
group: T1+T2+T3), and stage IV (with regard to the “rest of
stages”).Theypredictedahigherriskofmortality.Resultsare
shown in Table 2.
In the univariate model for recurrent disease, we also
found statistical signiﬁcance in the variables; capsule inva-
sion, prethyroid muscle involvement, positive cervical lymph
nodes,T4gr oupofTNM(withr egar dt otheT1gr oupandt o
the “rest of T” group; T1+T2+T3), and stage IV (with regard
tothestageIandtothe“restofstages”),andtotalcumulative
dose of radioiodine higher than 100 mCi. Results are shown
in Table 3.
In the multivariate model for survival, higher mortality
was related to stage IV compared to the “rest of stages” and
related to FC compared to PC. Results are shown in Table 4.
Survival curves are represented in Figures 1 and 2.
In the multivariate model for recurrent disease, higher
risk of recurrence was observed in patients with prethyroid
muscle involvement, positive cervical lymph nodes, and FC
compared to PC. Results are shown in Table 5.
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Figure 1: Survival curve of stage IV and rest of stages in the
multivariate analysis.
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Figure 2: Survival curve of pathological classiﬁcation in the
multivariate analysis.
The 5-year survival rate and the 10-year survival rate of
each signiﬁcant variable are given in Table 6.
4. Discussion
In Spain, the highest incidence of DTC has been described
in the region of Navarra. Values adjusted for age are 3.10
and 9.36 per 100000 inhabitants/year in men and women
respectively, between 1987 and 1997. In Germany, France,
and Italy [1], similar results were obtained due to early
diagnosis and thorough analysis of surgical tissues.4 ISRN Oncology
Table 1: General overview of main descriptive results.
Variables and their classiﬁcations Ratio
Age: younger than 45 years old 52.61%
Gender: women 80.00%
Presurgical FNAC: suspicious or malignant 75.00%
Tumor pathological classiﬁcation:
(i) Papillary carcinoma (mean age 42.90 years old, mean tumor size 21.75mm) 63.38%
(ii) Follicular carcinoma (mean age 49.56 years old, mean tumor size 40.89mm) 36.61%
Surgical treatment on the thyroid: total thyroidectomy 95.69%
Surgical treatment of cervical lymph node metastases 21.23%
Surgical complications:
(i) Recurrent nerve palsy 4.00%
(ii) Deﬁnitive hypoparathyroidism 1.80%
TNM classiﬁcation:
(i) T1: 125 patients 38.46%
(ii) T2: 97 patients 29.84%
(iii) T3: 61 patients 18.76%
(iv) T4: 42 patients 12.92%
(v) N0: 256 patients 78.76%
(vi) N1: 69 patients 21.23%
Stages:
(i) I: 207 patients 63.69%
(ii) II: 48 patients 14.76%
(iii) III: 40 patients 12.30%
(iv) IV: 30 patients 9.23%
(a) IV a: 21 patients 6.40%
(b) IV c: 9 patients 2.80%
(v) Stage I and II 78.46%
Radioiodine treatment 97.53%
Positive antithyroglobulin autoantibodies 6.77%
Complete remission 77.55%
Mortality 4.00%
Persistent/recurrent disease 3.69%
FNAC: ﬁne needle aspiration cytology.
Table 2: Univariate model for survival.
Univariate model for survival P Hazard ratio HR 95% CI
Lower Upper
Age 0.056 79.9 0.8 7157.7
Thyroid capsule invasion 0.000 9.2 3.1 27.5
Muscle involvement 0.000 12.1 4.0 36.4
Tumor size; >40mm versus <20mm 0.033 10.3 1.2 88.3
T4 versus T1 (TNM) 0.003 24.1 2.9 195.9
T4 versus rest of T (TNM) 0.000 10.9 3.4 34.5
Stage IV versus rest of stages 0.000 20.3 6.6 62.3
Our research included patients diagnosed, treated, and
followed for 17 years in a Thyroid Disease Unit. Therefore,
we got quite a good number of subjects and the management
by a functional unit made possible to use identical protocols
and to initiate little changes according to current external
guidelines. Also, patients dying because of their DTC may
have died during those 17 years and recurrences or persistent
disease should have been evident, because two thirds of
those situations appear within the 10 years following surgery
[16, 17]. That long-term follow-up is a positive aspect of our
study to bear in mind [14].
In relation to gender, we were able to prove that women
were more aﬀected (80%), with a women/men ratio of 4/1,
somewhat higher than previously described; Ponce MarcoISRN Oncology 5
Table 3: Univariate model for persistent/recurrent disease.
Univariate model for persistent/recurrent disease P Hazard ratio HR 95% CI
Lower Upper
Thyroid capsule invasion 0.000 5.3 2.7 10.2
Muscle involvement 0.000 6.9 3.6 13.4
Positive lymph nodes 0.000 3.7 1.9 7.0
T4 versus T1 (TNM) 0.000 4.3 2.0 9.4
T4 versus rest of T (TNM) 0.000 5.4 2.8 10.5
Stage IV versus rest of stages 0.001 3.5 1.6 7.4
Table 4: Multivariate model for survival.
Multivariate model for survival. BP Hazard ratio HR 95% CI
Lower Upper
Stage IV versus rest of stages 3.284 0.000 26.674 8.643 82.322
Follicular versus papillary ca. 1.439 0.012 4.216 1.366 13.008
H¨ urthle versus papillary ca. −13.556 0.983 0.000 0.000
Table 5: Multivariate model for persistent/recurrent disease.
Multivariate model for persistent/recurrent disease BP Hazard ratio HR 95% CI
Lower Upper
Muscle involvement 1.851 0.000 6.366 3.106 13.047
Positive lymph nodes 1.154 0.002 3.172 1.520 6.619
Follicular versus papillary ca. 0.821 0.049 2.274 1.005 5.146
Table 6: Survival rates of signiﬁcant variables.
Variable
5-year
survival rate
(%)
10-year
survival rate
(%)
Stage IV 96.7 93
Rest of stages 99.9 99.8
Follicular carcinoma 97.7 95.3
Papillary carcinoma 99.5 98.8
Thyroid capsule invasion 92 85
Thyroid capsule not invaded 99 98
Muscle involvement 90 82
Muscle not involved 99 98
Tumor size >40mm 95.5 94
Tumor size <20mm 99.6 99.3
T4 (TNM) 91.5 86
Rest of T (TNM) 99.5 99
T1 (TNM) 99.6 99.3
[2] and Sitges Serra and Sancho Inserser [3]h a v er e p o r t e d
a ratio of 2/1, without providing any explanation for
diﬀerences. Gender distribution in the general population
cannot justify it because in Navarra and in their region it
is similar. Even though female life expectancy is longer than
male’s in our area, DTC [18–23] was detected mainly in
young people.
Most of the people were young. Scheiden et al. [24]
have observed similar data in Luxemburg (1990–1999); 310
subjects had a mean age of 48.3 years old, with a PC
increase from 1997 due to an early diagnosis in opinion of
the authors. Our association between age and survival was
nearly statistically signiﬁcant. Given that more than 50%
were younger than 45 years old and none of them had died
during follow-up, we obtained a distorted statistical model.
So, we propose that young age could have an important
positive predictive value on survival.
Regarding diagnosis, FNAC is considered the test of
choice by expert panels [2, 3]. In our work, it has been
malignant or suspicious in 75%, with an increased value
when performed in recent years probably because high-
resolutionUS[25]wasintroducedforearlydetectionoflocal
recurrence, for diagnosis of lymph node metastases, and for
guiding FNAC [26]. At the end of the study, we obtained a
false positive result in 1% and a false negative result in 5%.
In our patients, most tumors were PC. However, we
found a more elevated rate of FC than in previous studies
[2, 3, 18–23, 27]. Its cause remains unknown to us. Perhaps
it could be explained by a higher prevalence of FC in
immigrants or stronger environmental factors for goiter in
some areas of our region. We advise supplementing diet with
iodine and updating epidemiological research focused on
understanding it.
We did not ﬁnd statistical association between surgi-
cal procedure and survival. Except for 14 patients, in every
case total thyroidectomy was executed, with subsequent6 ISRN Oncology
radioiodine treatment if needed and hormone suppression
[28].
The number of lymphadenectomies registered is not
too high (66 cases). Nevertheless, we must remember that
routine cervical level VI dissection in papillary carcinoma
was widely accepted not long before this study was ﬁnished.
For Mazzaferri and Kloos [29], mediastinal and cervical
bilateral lymph node metastases modify recurrences and
survival as independent predictors and speciﬁc surgery on
lymph areas improves those items. In our series, cervical
l y m p hn o d em e t a s t a s e si m p a i rr e c u r r e n c e sb u tn o ts u r v i v a l .
This tumor stage has traditionally been treated surgically,
both in the initial diagnosis and lymph node recurrence.
Surgical morbidity keeps on being a worrying topic.
Sancho Fornos et al. [23] have published a meta-analysis
about benign and malignant goiter surgery; in best series, he
found 1.5% nerve injury and 0–2% deﬁnitive hypocalcemia.
But when level VI lymphadenectomy is associated, nerve
injury rises to 3–4% and hypocalcemia reaches 14–17%. In
our work, there is an intermediate morbidity in relation to
those previous results. We believe that factors that might
contribute are the observational nature of the study (historic
cohort),severalsurgeonsandresidentsurgeonsimplicatedin
treatment, and the later recommendation of level VI lymph
node dissection [30].
Looking back to the relevance of age within stages and
early diagnosis for prognosis, it is worthwhile remembering
that more than half of the population were under 45 years
old. Moreover, diagnosis came earlier in most cases (63.69%
belong to stage I). These circumstances may explain the
survival for both kinds of DTC. Our survival rate can be
related to previous works; Beasley et al. [31]h a v er e p o r t e d
no deaths in stage I and a mean age in patients dying from
their DTC of 68.5 years old.
Interpretation of negative eﬀect of a radioiodine treat-
ment dose over 100 mCi on persistent disease can be under-
stood because more aggressive tumors force us to use higher
doses of it. Also recurrences are treated with several sessions
of radioiodine and in that way the total dose is increased.
Even though this variable showed statistical signiﬁcance as
mentioned before, we do not include it in Table 3 because
of the chronological opposite relationship. Analysis of pos-
itive antithyroglobulin antibodies did not reach statistical
signiﬁcance, maybe because of the low sample size. However,
those tumors seemed to be more aggressive after studying
descriptive data.
Studying outcomes according to former characteristics,
every subject developing persistent/recurrent disease was
diagnosed with PC (12 cases). Ten of them were under 45
years old. Within related aggressive factors, we can describe
6 patients with worse PC variants (2 of tall-cells and
4o fd i ﬀuse sclerosant), 7 with positive cervical lymph
adenopathiesatdiagnosis,5withthyroidcapsuleinﬁltration,
5 were multifocal tumors, and 5 with prethyroid muscle
involvement. In all of them, persistent/recurrent disease
consisted of locoregional spread (thyroid bed and cervical
lymphadenopathies), and so were surgically treated. Stojadi-
novic et al. [32] have reported the follow-up of 431 recurrent
DTC during 13 years, ﬁnding a 35% local recurrence, 23%
local and regional recurrence, and 30% local and distance
recurrence. Symptoms were evident only in 26%. They
conclude that survival can be predicted by age under 45
years old, subclinical or local recurrence, and the ability
of maintaining the disease-free situation. Mazzaferri and
Jhiang [14] have published a follow-up of 30 years and
show a survival of 76% and 30% recurrences. Mortality
increased every decade over 40 years old. The recurrent
d i s e a s ea p p e a r e dm o r eo f t e ni na g eu n d e r2 0a n do v e r5 9
years old. In our series, DTC was the cause of death in
every patient suﬀering from distant metastases. We counted
13 (4%) DTC total deaths; 9 (2.8%) with distant disease
and 5 (1.5%) with local recurrence. Only one patient died
suﬀering from local and distant recurrence. When patients
showedsymptoms orwereclassiﬁedinstageIVatthe time of
diagnosis, we observed the above-mentioned bad prognosis.
This group had a mean age of 68.3 years old.
Some workshops and expert panels have suggested risk
classiﬁcations, both through a few parameters for grouping
patients and through many clinical data providing complex
systems [33, 34]. Probably, the most used risk classiﬁcation
for clinicians during follow-up is the one based on basal
or stimulated Tg detection. Mazzaferri et al. [33]h a v e
deﬁned a group of disease-free patients when Tg is below
0.5ng/mL (60–70% of patients), a group of patients needing
close follow-up if Tg is 0.6 to 2ng/mL (15–20%), and a
group likely to show local or distant recurrence or persistent
disease if Tg is over 2ng/mL (20–25%). Schlumberger et al.
[34] have also supplied risk factors for recurrence; tumor
size larger than 20mm and/or with cervical locoregional
spread. Prospective studies have shown that patients with
undetectable Tg and negative cervical US show a less 0.5%
risk of 10-year recurrence rate. S´ anchez Franco [13]h a s
demonstrated that this risk increases as tumoral stage does.
This statement can be considered a brief general concept,
present in many studies.
5. Conclusions
Our results allow us to classify patients in three risk groups
deﬁned as follows.
(i) A group with a better long-term prognosis would be
composed of subjects younger than 45 years old, with
PC diagnosed in FNAC, and with DTC detected in
early stages (T1 to T3, smaller than 40mm, negative
cervical lymph nodes and without capsule or muscle
involvement).
(ii) A group with a higher risk of recurrent disease,
but not higher mortality, would be represented by
thosepatientswithpositivecervicallymphnodesand
those who have received a total cumulative dose of
radioiodine more elevated.
(iii) A group with higher risk of recurrence and death
would be composed of patients of 45 years old or
older, with FC and advanced stage (stage IV, T4 or
larger than 40mm, with capsule or muscle invasion).ISRN Oncology 7
Inouropinion, thisclassiﬁcationcouldhelpinguidingtreat-
mentandfollow-up;frequencyofout-patientvisitsandneed
of complementary examinations, being aware of methodo-
logical limits from any observational research.
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